Concepedia

Lawrence Galitz

LG

9

Publications

838

Citations

9

H-Index

2004

Active since

Affiliations

Novartis (United States)(Current)

National Parkinson's Foundation

Lawrence Galitz is an author at Novartis (United States) specializing in pharmacotherapy, medicine, and pharmacology.

Top concepts

Publications per year

2004–2021

9

Publications

9

Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Ioanna Gouni‐Berthold, Veronica J. Alexander, Qingqing Yang et al. · The Lancet Diabetes & Endocrinology · 2021 · 211 citations

, , +1

Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib

Chiaki Tanaka, Ophelia Yin, Venkat Sethuraman et al. · Clinical Pharmacology & Therapeutics · 2009 · 179 citations

Helicase–Primase Inhibitor Pritelivir for HSV-2 Infection

Anna Wald, Lawrence Corey, Burkhard Timmler et al. · New England Journal of Medicine · 2014 · 159 citations

Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment

Gregory B. Holmes, Lawrence Galitz, Peter Hu et al. · British Journal of Clinical Pharmacology · 2005 · 85 citations · Full text

Effects of Rifampin and Ketoconazole on the Pharmacokinetics of Nilotinib in Healthy Participants

Chiaki Tanaka, Ophelia Yin, Tom Smith et al. · The Journal of Clinical Pharmacology · 2010 · 68 citations

, , +21

Rows per page

1–5 of 9